5 Healthcare Stocks Under $10 Ready To Pop

Orexigen Therapeutics, Inc. (NASDAQ:OREX) occupies the fourth spot, as a total of 28 hedge funds had an aggregate investment of $145.85 million at the end of June in the biopharmaceutical company engaged in developing therapeutic drugs for the treatment of obesity. The popularity of the company rose considerably during the second quarter, as just 24 firms had investments worth $184.87 million in Orexigen Therapeutics, Inc. (NASDAQ:OREX) at the end of March. The rise in interest has come despite an almost 36% drop in stock price during the second trimester, which indicates elite investors believe a great entry point has been found and that the stock will reverse course. Each of the top three stockholders of the company were extremely bullish on it, with Robert Pohly‘s Samlyn Capital having the largest holding after hiking its stake by 93% to 6.05 million shares valued at $29.93 million.